BET and Aurora Kinase A inhibitors synergize against MYCN-positive human glioblastoma cells

Combined BET bromodomain and CDK2 inhibition in MYC-driven medulloblastoma

(2018) Sara Bolin et al.   ONCOGENE

Towards Improvements for Penetrating the Blood–Brain Barrier—Recent Progress from a Material and Pharmaceutical Perspective

(2018) Quanguo He et al.   Cells

Dual BRD4 and AURKA Inhibition Is Synergistic against MYCN-Amplified and Nonamplified Neuroblastoma

(2018) Joshua Felgenhauer et al.   NEOPLASIA

LGR5 promotes tumorigenicity and invasion of glioblastoma stem-like cells and is a potential therapeutic target for a subset of glioblastoma patients

(2018) Yuan Xie et al.   JOURNAL OF PATHOLOGY

Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma

(2017) Roger Stupp et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Lomustine and Bevacizumab in Progressive Glioblastoma

(2017) Wolfgang Wick et al.   NEW ENGLAND JOURNAL OF MEDICINE

LGR5 promotes cancer stem cell traits and chemoresistance in cervical cancer

(2017) Hao-Zhe Cao et al.   Cell Death & Disease

Olig2-Dependent Reciprocal Shift in PDGF and EGF Receptor Signaling Regulates Tumor Phenotype and Mitotic Growth in Malignant Glioma

(2016) Fanghui Lu et al.   CANCER CELL

Clonal Variation in Drug and Radiation Response among Glioma-Initiating Cells Is Linked to Proneural-Mesenchymal Transition

(2016) Anna Segerman et al.   Cell Reports

Myc and cell cycle control

(2015) Gabriel Bretones et al.   Biochimica et Biophysica Acta-Gene Regulatory Mechanisms

The Human Glioblastoma Cell Culture Resource: Validated Cell Models Representing All Molecular Subtypes

(2015) Yuan Xie et al.   EBioMedicine

Reconstructing and Reprogramming the Tumor-Propagating Potential of Glioblastoma Stem-like Cells

(2014) Mario L. Suvà et al.   CELL

Emerging treatment strategies for glioblastoma multiforme

(2014) S. K. Carlsson et al.   EMBO Molecular Medicine

The Mechanisms behind the Therapeutic Activity of BET Bromodomain Inhibition

(2014) Junwei Shi et al.   MOLECULAR CELL

Myc inhibition is effective against glioma and reveals a role for Myc in proficient mitosis

(2014) Daniela Annibali et al.   Nature Communications

Inhibition of BET Bromodomain Targets Genetically Diverse Glioblastoma

(2013) Z. Cheng et al.   CLINICAL CANCER RESEARCH

BET Bromodomain Inhibition of MYC-Amplified Medulloblastoma

(2013) P. Bandopadhayay et al.   CLINICAL CANCER RESEARCH

Inhibition of Myc family proteins eradicates KRas-driven lung cancer in mice

(2013) L. Soucek et al.   GENES & DEVELOPMENT

Brain tumor stem cells: Molecular characteristics and their impact on therapy

(2013) David L. Schonberg et al.   MOLECULAR ASPECTS OF MEDICINE

Akt and c-Myc Induce Stem-Cell Markers in Mature Primary p53−/− Astrocytes and Render These Cells Gliomagenic in the Brain of Immunocompetent Mice

(2013) Josefine Radke et al.   PLoS One

Targeting MYCN in Neuroblastoma by BET Bromodomain Inhibition

(2013) Alexandre Puissant et al.   Cancer Discovery

MYC on the Path to Cancer

(2012) Chi V. Dang   CELL

Aurora A is differentially expressed in gliomas, is associated with patient survival in glioblastoma and is a potential chemotherapeutic target in gliomas

(2012) Norman L. Lehman et al.   CELL CYCLE

Aurora A kinase (AURKA) in normal and pathological cell division

(2012) Anna S. Nikonova et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins

(2012) W. W. Lockwood et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Mosaic Analysis with Double Markers Reveals Tumor Cell of Origin in Glioma

(2011) Chong Liu et al.   CELL

BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc

(2011) Jake E. Delmore et al.   CELL

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

Chemoresistance to Temozolomide in Human Glioma Cell Line U251 is Associated with Increased Activity of O 6-methylguanine-DNA Methyltransferase and Can be Overcome by Metronomic Temozolomide Regimen

(2011) Qiang Pan et al.   CELL BIOCHEMISTRY AND BIOPHYSICS

The proliferation rate paradox in antimitotic chemotherapy

(2011) Timothy J. Mitchison   MOLECULAR BIOLOGY OF THE CELL

Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma

(2010) Houtan Noushmehr et al.   CANCER CELL

Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1

(2010) Roel G.W. Verhaak et al.   CANCER CELL

Stabilization of N-Myc Is a Critical Function of Aurora A in Human Neuroblastoma

(2009) Tobias Otto et al.   CANCER CELL

Mechanisms of Chemoresistance to Alkylating Agents in Malignant Glioma

(2008) J. N. Sarkaria et al.   CLINICAL CANCER RESEARCH

c-Myc Is Required for Maintenance of Glioma Cancer Stem Cells

(2008) Jialiang Wang et al.   PLoS One